Sharon Rosenzweig-Lipson, PhD profile page

Dr. Sharon Rosenzweig-Lipson is chief scientific officer of Life Biosciences, a clinical-stage biotechnology company pioneering cellular rejuvenation therapies to reverse and prevent multiple diseases of aging. She earned her BA in the biological basis of behavior from the University of Pennsylvania and her PhD in psychology (behavioral neuroscience) from Harvard University. She has held leadership positions at both large pharmaceutical and small biotechnology companies throughout her 30-year career. Rosenzweig-Lipson has a proven track record of advancing programs from the early exploratory phase through to Phase 2b trials. Her career has included time at American Cyanamid, American Home Products, Wyeth, and Pfizer, where she led a team to a successful Phase 2 proof-of-concept study and served as site head at Princeton. As vice president of research and development for AgeneBio, Rosenzweig-Lipson led the clinical development of its lead asset through Phase 2b clinical trials, as well as managing the company’s preclinical discovery program. Having led global translational alliances, Rosenzweig-Lipson is globally recognized for her top scientific and strategic leadership. She has a strong publication and patent record. One of her key focuses is building high-quality, integrated, cross-functional teams utilizing both internal and external talent to deliver programs in a timely manner.